[
    [
        {
            "time": "",
            "original_text": "兼并重组大势下，医药连锁行业迎巨变，健之佳胃口仅是“西南”？",
            "features": {
                "keywords": [
                    "兼并重组",
                    "医药连锁",
                    "健之佳",
                    "西南"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "零售"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "兼并重组大势下，医药连锁行业迎巨变，健之佳胃口仅是“西南”？",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "西南证券---医药行业2021年一季度业绩前瞻：CXO、器械、药店等有望延续高增长【行业研究】",
            "features": {
                "keywords": [
                    "西南证券",
                    "医药行业",
                    "CXO",
                    "器械",
                    "药店",
                    "高增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技",
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券---医药行业2021年一季度业绩前瞻：CXO、器械、药店等有望延续高增长【行业研究】",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]